- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01286467
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
August 9, 2023 updated by: Pfizer
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF 04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT SOLID TUMORS
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select solid tumors.
Study Overview
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Keck Hospital of University of Southern California
-
Los Angeles, California, United States, 90033
- Los Angeles County-University of Southern California Medical Center
-
Los Angeles, California, United States, 90033
- University of Southern California/Norris Comprehensive Cancer Center
-
Los Angeles, California, United States, 90033
- University of Southern California/Norris Comprehensive Cancer Center/Investigational Drug Service
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Denver
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospital
-
Aurora, Colorado, United States, 80045
- Anschutz Cancer Pavilion
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute (DFCI)
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital (BWH)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histological or cytological diagnosis of advanced/metastatic solid tumor
- Adequate Bone Marrow Function
- Adequate Renal Function
- Adequate Liver Function
Exclusion Criteria:
- Patients with known symptomatic brain metastases requiring steroids
- Current active treatment on another clinical trial
- Major surgery or radiation therapy within 4-weeks of starting study treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With First Cycle Dose Limiting Toxicities (DLTs)
Time Frame: Baseline up to end of Cycle 1 (Study Day 28)
|
Any DLT event in Cycle 1: (1) Grade 4 neutropenia lasting more than 7 days; (2) Febrile neutropenia; (3) Grade >=3 neutropenic infection; (4) Grade >=3 thrombocytopenia with bleeding; (5) Grade 4 thrombocytopenia lasting more than 7 days; (6) Grade >=3 non-hematologic toxicity; (7) Failure to deliver at least 80% of the planned doses due to toxicities attributable to PF-04449913
|
Baseline up to end of Cycle 1 (Study Day 28)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Treatment-emergent Adverse Events (AEs), by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) Grade
Time Frame: Baseline up to 28 days post last dose of study medication (maximum duration: 14 cycles [each cycle of 28 days])
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Treatment-emergent AEs are events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
If the same participant in a given treatment had more than one occurrence in the same preferred term event category, only the worst CTCAE grade was reported.
Grades as per NCI CTCAE, v4.0 were classified as: Grade 1- mild, Grade 2- moderate, Grade 3- severe, Grade 4- life threatening, and Grade 5- death.
|
Baseline up to 28 days post last dose of study medication (maximum duration: 14 cycles [each cycle of 28 days])
|
Percentage of Participants With Treatment-related AEs, by NCI CTCAE (Version 4.0) Grade
Time Frame: Baseline up to 28 days post last dose of study medication (maximum duration: 14 cycles [each cycle of 28 days])
|
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.
Treatment-related AEs are events that were assessed by the investigator as related to study medication.
If the same participant in a given treatment had more than one occurrence in the same preferred term event category, only the worst CTCAE grade was reported.
Grades as per NCI CTCAE, v4.0 were classified as: Grade 1- mild, Grade 2- moderate, Grade 3- severe, Grade 4- life threatening, and Grade 5- death.
|
Baseline up to 28 days post last dose of study medication (maximum duration: 14 cycles [each cycle of 28 days])
|
Hedgehog Biomarker Modulation: Relative GLI1 Gene Expression (Ratio) to Baseline for Normal Skin on Cycle 1/Day 15
Time Frame: Baseline and Cycle 1/Day 15
|
Ribonucleic acid (RNA) was extracted from skin samples and complementary deoxyribonucleic acid (cDNA) was prepared.
Gene expression was measured using custom Taqman low density array (TLDA) cards run on the Applied Biosystems ViiATM 7 system.
The ratio for each participant at each dosing level was calculated at C1D15 to baseline assay readout (C1D1), and the mean of it is reported in this outcome measure.
|
Baseline and Cycle 1/Day 15
|
Maximum Observed Plasma Concentration (Cmax) on Cycle 1/Day 1
Time Frame: Pre dose, 1, 2, 4, 6, 10 and 24 hours post dose on Cycle 1/Day 1
|
Cmax of PF-04449913 on Cycle 1/Day 1 has been reported.
|
Pre dose, 1, 2, 4, 6, 10 and 24 hours post dose on Cycle 1/Day 1
|
Maximum Observed Plasma Concentration (Cmax) on Cycle 1/Day 25
Time Frame: Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Cmax of PF-04449913 on Cycle 1/Day 25 has been reported.
|
Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Cycle 1/Day 1
Time Frame: Pre dose, 1, 2, 4, 6, 10 and 24 hours post dose on Cycle 1/Day 1
|
Tmax of PF-04449913 on Cycle 1/Day 1 has been reported.
|
Pre dose, 1, 2, 4, 6, 10 and 24 hours post dose on Cycle 1/Day 1
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Cycle 1/Day 25
Time Frame: Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Tmax of PF-04449913 on Cycle 1/Day 25 has been reported.
|
Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Cycle 1/Day 1
Time Frame: Pre dose, 1, 2, 4, 6, 10 and 24 hours post dose on Cycle 1/Day 1
|
AUCtau of PF-04449913 on Cycle 1/Day 1 has been reported.
AUCtau is defined as area under the curve from time 0 to tau, where tau is the dosing interval of 24 hours.
|
Pre dose, 1, 2, 4, 6, 10 and 24 hours post dose on Cycle 1/Day 1
|
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Cycle 1/Day 25
Time Frame: Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
AUCtau of PF-04449913 on Cycle 1/Day 25 has been reported.
AUCtau is defined as area under the curve from time 0 to tau, where tau is the dosing interval of 24 hours.
|
Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Plasma Decay Half-life (t1/2) on Cycle 1/Day 25
Time Frame: Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
|
Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Apparent Oral Clearance (CL/F) on Cycle 1/Day 25
Time Frame: Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
|
Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Apparent Volume of Distribution (Vz/F) on Cycle 1/Day 25
Time Frame: Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
|
Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Accumulation Ratio (Rac) on Cycle 1/Day 25
Time Frame: Pre dose, 1, 2, 4, 6, 10 and 24 hours post dose on Cycle 1/Day 1, and pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Accumulation ratio was calculated as AUCtau at steady state (Cycle 1/Day 25)/AUCtau on Study Day 1
|
Pre dose, 1, 2, 4, 6, 10 and 24 hours post dose on Cycle 1/Day 1, and pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Average Concentration at Steady State (Cavg) on Cycle 1/Day 25
Time Frame: Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
Pre dose, 1, 2, 4, 10, 24, 48, 72 and 96 hours post dose on Cycle 1/Day 25
|
|
Number of Participants With Increase From Baseline in Corrected QT Using Fridericia's Formula (QTcF) Interval
Time Frame: Baseline up to Cycle 14 (each cycle 28 days)
|
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.
The time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole (QT) was corrected for heart rate (QTc).
QTc using Fridericia's formula (QTcF) was calculated.
Participants with maximum increase from baseline of less than (<) 30 millisecond (msec), 30 to <60 msec and >=60 msec were summarized.
|
Baseline up to Cycle 14 (each cycle 28 days)
|
Number of Participants With Decrease From Baseline in QTcF Interval
Time Frame: Baseline up to Cycle 14 (each cycle 28 days)
|
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.
QTcF was calculated.
Participants with maximum decrease from baseline of <30 msec, 30 to <60 msec and >=60 msec were summarized.
|
Baseline up to Cycle 14 (each cycle 28 days)
|
Number of Participants With Post-baseline QTcF Interval Greater Than or Equal to 500 Msec
Time Frame: Baseline up to Cycle 14 (each cycle 28 days)
|
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.
Participants with post-baseline absolute QTcF values >=500 msec were summarized.
|
Baseline up to Cycle 14 (each cycle 28 days)
|
Percentage of Participants With Objective Response
Time Frame: Baseline up to Cycle 14 (each cycle 28 days)
|
Percentage of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response.
CR was defined as complete disappearance of all target lesions with the exception of nodal disease.
PR was defined as >=30% decrease under baseline of the sum of diameters of all target measurable lesions.
|
Baseline up to Cycle 14 (each cycle 28 days)
|
Progression-Free Survival (PFS)
Time Frame: Baseline up to Cycle 14 (each cycle 28 days)
|
Time from Cycle 1/Day 1 to first documentation of disease progression or to death due to any cause, whichever occurred first.
Progression was defined using RECIST 1.1 as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
PFS (days) was calculated as (first event date minus the date of first dose of study medication plus 1).
|
Baseline up to Cycle 14 (each cycle 28 days)
|
Time to Progression (TTP)
Time Frame: Baseline up to Cycle 14 (each cycle 28 days)
|
Time from Cycle 1/Day 1 to first documentation of disease progression.
Progression was defined using RECIST 1.1 as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
TTP (days) was calculated as (first event date minus the date of first dose of study medication plus 1).
|
Baseline up to Cycle 14 (each cycle 28 days)
|
Duration of Response (DR)
Time Frame: Baseline up to Cycle 14 (each cycle 28 days)
|
Duration from date of first documentation of objective response to date of first documentation of disease progression or death.
Progression was defined using RECIST 1.1 as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
DR was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first objective response that was subsequently confirmed plus 1).
|
Baseline up to Cycle 14 (each cycle 28 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Fostvedt LK, Shaik N, Martinelli G, Wagner AJ, Ruiz-Garcia A. Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. Expert Rev Clin Pharmacol. 2021 Jul;14(7):927-935. doi: 10.1080/17512433.2021.1925538. Epub 2021 May 18.
- Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry AB. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 1;21(5):1044-51. doi: 10.1158/1078-0432.CCR-14-1116. Epub 2014 Nov 11.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 11, 2011
Primary Completion (Actual)
May 10, 2012
Study Completion (Actual)
December 28, 2012
Study Registration Dates
First Submitted
January 14, 2011
First Submitted That Met QC Criteria
January 27, 2011
First Posted (Estimated)
January 31, 2011
Study Record Updates
Last Update Posted (Actual)
March 6, 2024
Last Update Submitted That Met QC Criteria
August 9, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B1371002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia
Clinical Trials on PF-04449913
-
Fred Hutchinson Cancer CenterPfizerTerminatedChronic Graft Versus Host Disease | FasciitisUnited States
-
PfizerCompletedHematologic MalignanciesUnited States, Italy
-
PfizerCompleted
-
Grupo Espanol de trasplantes hematopoyeticos y...Active, not recruitingSclerodermoid Chronic Graft-Versus-Host Disease (Disorder)Spain
-
PfizerTerminatedPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia MyelofibrosisUnited States, Japan
-
University of Colorado, DenverThe Leukemia and Lymphoma SocietyCompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in RemissionUnited States
-
H. Lee Moffitt Cancer Center and Research InstitutePfizerCompletedChronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)United States
-
Genzyme, a Sanofi CompanyActive, not recruitingGaucher Disease Type 1 | Gaucher Disease Type 3Germany, United States, Japan, United Kingdom
-
PfizerCompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic SyndromeUnited States, United Kingdom, Belgium, Canada, Germany, France
-
PfizerCompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic SyndromeSpain, Canada, Austria, Czechia, France, Hungary, Italy, Japan, Mexico, Poland, United Kingdom